scholarly journals A literature survey on Cost-Effectiveness of Proton Beam Therapy in the Management of Breast Cancer Patients

2015 ◽  
Vol 8 (6) ◽  
Author(s):  
Reza Reiazi ◽  
Amir Norozi
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Cancer Patients ◽  
Proton Beam ◽  
Proton Beam Therapy ◽  
Literature Survey ◽  
Breast Cancer Patients

scholarly journals The role of proton beam therapy in the management of elderly breast cancer patients

2020 ◽  
Vol 9 (S1) ◽  
pp. S161-S172
Author(s):  
Benjamin J. Rich ◽  
David Asher ◽  
Bosco Giap ◽  
Huan Giap
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Proton Beam ◽  
Proton Beam Therapy ◽  
Breast Cancer Patients

scholarly journals Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Qiaoping Xu ◽  
Li Yuanyuan ◽  
Zhu Jiejing ◽  
Liu Jian ◽  
Li Qingyu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Partial Response ◽  
Cancer Patients ◽  
Transition Probabilities ◽  
Complete Response ◽  
Sensitivity Analyses ◽  
Half Cycle ◽  
Breast Cancer Patients ◽  
Grade 3

Abstract Background Breast cancer is the most common cancer among women in China. Amplification of the Human epidermal growth factor receptor type 2 (HER2) gene is present and overexpressed in 18–20% of breast cancers and historically has been associated with inferior disease-related outcomes. There has been increasing interest in de-escalation of therapy for low-risk disease. This study analyzes the cost-effectiveness of Doxorubicin/ Cyclophosphamide/ Paclitaxel/ Trastuzumab (AC-TH) and Docetaxel/Carboplatin/Trastuzumab(TCH) from payer perspective over a 5 year time horizon. Methods A half-cycle corrected Markov model was built to simulate the process of breast cancer events and death occurred in both AC-TH and TCH armed patients. Cost data came from studies based on a Chinese hospital. One-way sensitivity analyses as well as second-order Monte Carlo and probabilistic sensitivity analyses were performed.The transition probabilities and utilities were extracted from published literature, and deterministic sensitivity analyses were conducted. Results We identified 41 breast cancer patients at Hangzhou First People’s Hospital, among whom 15 (60%) had a partial response for AC-TH treatment and 13 (81.25%) had a partial response for TCH treatment.No cardiac toxicity was observed. Hematologic grade 3 or 4 toxicities were observed in 1 of 28 patients.Nonhematologic grade 3 or 4 toxicities with a reverse pattern were observed in 6 of 29 patients. The mean QALY gain per patient compared with TCH was 0.25 with AC-TH, while the incremental costs were $US13,142. The incremental cost-effectiveness ratio (ICER) of AC-TH versus TCH was $US 52,565 per QALY gained. Conclusions This study concluded that TCH neoadjuvant chemotherapy was feasible and active in HER2-overexpressing breast cancer patients in terms of the pathological complete response, complete response, and partial response rates and manageable toxicities.

The cost-effectiveness of a nurse-led care program for breast cancer patients undergoing outpatient-based chemotherapy – A feasibility trial

2018 ◽  
Vol 36 ◽  
pp. 16-25 ◽  
Author(s):  
Xiao Bin Lai ◽  
Shirley Siu Yin Ching ◽  
Frances Kam Yuet Wong ◽  
Carenx Wai Yee Leung ◽  
Lai Ha Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Cancer Patients ◽  
Care Program ◽  
Feasibility Trial ◽  
Breast Cancer Patients ◽  
The Cost

scholarly journals Cost-effectiveness of using protons in breast cancer patients aiming at reducing cardiotoxicity: A risk-stratification analysis

2021 ◽  
Author(s):  
Guo Li ◽  
Yun-Fei Xia ◽  
Yi-Xiang Huang ◽  
Deniz Okat ◽  
Bo Qiu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Cost Effectiveness ◽  
Cancer Patients ◽  
Cost Effective ◽  
Cardiac Risk ◽  
Cardiac Risk Factor ◽  
General Level ◽  
Breast Cancer Patients ◽  
Intensity Modulated

Abstract Purpose Incidental exposure of heart to ionizing irradiation is associated with an increased risk of ischemic heart disease (IHD) in breast cancer patients after radiotherapy. Intensity-modulated proton radiation therapy (IMPT) offers a promise in limiting the mean heart dose (MHD) in breast irradiation to a negligible level. However, the uncertainty in cost-effectiveness hinders its use. This cost-effectiveness analysis aims to identify patients in appropriate risk groups as targets for IMPT. Methods A Markov decision model was designed to evaluate the cost-effectiveness of IMPT versus intensity-modulated photon-radiation therapy (IMRT) in reducing the irradiation-related IHD risk. Baseline evaluation was performed on 50-year-old women patient without preexisting cardiac risk factor (CRF). Stratified for preexisting cardiac risk and photon MHD, cost-effective scenarios under different proton cost and willingness-to-pay (WTP) were identified for 40-, 50- and 60-year-old patients. Results With baseline set-ups, incremental effectiveness (IE) ranged from 0.025 quality-adjusted life-year (QALY) to 0.135 QALY when photon MHD varied from 3 to 16 Gy; IE increased from 0.043 QALY to 0.964 QALY when preexisting cardiac risk increased from the baseline level to its 10 times. IMPT was not cost-effective to patients without preexisting CRF. At the WTP of China, once proton cost reduced to $20,000, IMPT would be cost-effective to ≤ 50-year-old women patients having preexisting cardiac risk of general-population level. Conclusion Patient’s preexisting cardiac risk level should be a main consideration for the clinical decision of using protons; protons may become cost-effective to general-level patients if a substantial decrease in proton cost occurs in the future.

scholarly journals Individualised selection of left‐sided breast cancer patients for proton therapy based on cost‐effectiveness

2020 ◽  
Author(s):  
Annabelle M. Austin ◽  
Michael J.J. Douglass ◽  
Giang T. Nguyen ◽  
Lisa Cunningham ◽  
Hien Le ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Cancer Patients ◽  
Proton Therapy ◽  
Breast Cancer Patients ◽  
Selection Of
Sign in / Sign up

Export Citation Format

Share Document